Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2011-05-31
2011-05-31
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S133100, C424S135100, C424S141100, C424S142100, C424S145100
Reexamination Certificate
active
07951372
ABSTRACT:
Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5536637 (1996-07-01), Jacobs
patent: 5674487 (1997-10-01), Smith et al.
patent: 5837232 (1998-11-01), DeWaal Malefyt et al.
patent: 5863796 (1999-01-01), Moore et al.
patent: 6143867 (2000-11-01), Akerblom
patent: 6225117 (2001-05-01), Gately et al.
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 6331613 (2001-12-01), Dumoutier et al.
patent: 6359117 (2002-03-01), Dumoutier et al.
patent: 6551799 (2003-04-01), Gurney et al.
patent: 2001/0006637 (2001-07-01), Akahoshi et al.
patent: 2001/0023070 (2001-09-01), Ebner et al.
patent: 2001/0024652 (2001-09-01), Dumoutier et al.
patent: 2002/0012669 (2002-01-01), Presnell et al.
patent: 2002/0102723 (2002-08-01), Gurney et al.
patent: 2002/0177165 (2002-11-01), Ashkenazi et al.
patent: 2002/0187523 (2002-12-01), Tang et al.
patent: 2003/0003545 (2003-01-01), Ebner et al.
patent: 2003/0012788 (2003-01-01), Renauld et al.
patent: 2003/0092133 (2003-05-01), Ebner et al.
patent: 2003/0170823 (2003-09-01), Presnell et al.
patent: 2004/0023341 (2004-02-01), Xu et al.
patent: 2004/0110189 (2004-06-01), Dumoutier et al.
patent: 2004/0152125 (2004-08-01), Presenell et al.
patent: 2004/0180399 (2004-09-01), Renauld et al.
patent: 2005/0042220 (2005-02-01), Li et al.
patent: 2007/0196370 (2007-08-01), Fouser et al.
patent: 2007/0258982 (2007-11-01), Fouser et al.
patent: WO 94/01548 (1994-01-01), None
patent: WO 99/61617 (1999-12-01), None
patent: WO 00/24758 (2000-05-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73457 (2000-12-01), None
patent: WO 00/77037 (2000-12-01), None
patent: WO 01/46422 (2001-06-01), None
patent: WO 02/10393 (2002-02-01), None
patent: WO 02/16611 (2002-02-01), None
Sugimoto et al. Gastroenterology: 2006: 130; 4: Suppl. 2: A41.
Sugimoto et al. Gastroenterology: 2005: 128: Suppl. 2: A18.
Van Deventer et al. Reaserach and Clinical Forums. 1998; 20; 11-18.
Andoh et al., “Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts”, Gastroenterology: 2005 129:969-84.
Brand et al. Am. J. Physiol. Gastrointest. Liver Physiol.: 2006: 290:G827-38.
Sugimoto et al., “IL-22 Ameliorates intestinal inmflammation in a mouse model of ulcerative colitis”, The Journal of Clinical Investigation: 2008: 118:534-44.
Carvahlo et al., Inflamm Bowel Dis. 2008; 14:1051-60.
Dumoutier et al., Absence of IL-22 aggravates dextran-sulfate [DSS] induced colitis; Abstract #42, Cytokine 43 (2008) 243-262.
Ouyang et al., Mucosal Immunology, 2008; 1:335-338.
Wolk et al., J Immunol. 2007; 178:5973-81.
Schmechel et al., Inflamm Bowel Dis. 2008; 14: 204-12.
Mahairas, G. et al., Database EST. Accession No. AQ104025. Aug. 28, 1998.
Waterston, R. et al., Database GenEmbl. Accession No. AC006734. Feb. 25, 1999.
Wilson, R. et al., J. Mol. Biol. 261:155-172, 1996.
Bork, et al., Trends in Genetics, 12:425-427, 1996.
Vukicevic, et al., PNAS USA 93:9021-9026, 1996.
Massague, J. Cell, 49:437-8, 1987.
Pilbeam, et al., Bone 14:717-720, 1993.
Skolnick, et al., Trends in Biotech. 18:34-39, 2000.
Dumoutier, et al. (2000), “Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9,” J. of Immunol. 164:1814-1819.
Syrbe, et al. (1999) Springer Seminars in Immunopathology, 21:263-85.
Dumoutier, L. et al., GenBank Accession No. NM—016971 formus musculusinterleukin 10-related T cell-derived inducible factor (Iltif). Jun. 8, 2000.
Aoki, I., et al. “Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins,” FEBS Lett. 282(1):56-60, 1991.
Dumoutier, L. et al., “Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor,” PNAS 97(18):10144-9, 2000.
Dumoutier, L. et al., “IL-TIF-/IL-22: genomic organization and mapping of the human and mouse genes,” Genes Immun. 1:488-494, 2000.
Ozaki, T. et al., GenBank Accession No. D13973 forDictyostelium discoideumDNA for Dp87 protein, 1993. Feb. 1, 2000.
Aoki, I. et al., GenBank Accession No. P35709 forEosinophilgranule major basic protein 2 percursor (mbp-2). May 30, 2000.
Xie, M. et al. GenBank Accession No. AF279437 forHomo sapiensinterleukin 22 (IL22). Oct. 9, 2000.
Dumoutier, L. et al., GenBank Accession No. AJ294727 forMus musculusILTIFa gene for IL TIE alpha protein (IL-22), exons 1a 5. Dec. 21, 2000.
Dumoutier, L. et al., GenBank Accession No. NP—065386 for Interleukin 22: IL-10 related T-cell derived inducible factor (Homo sapiens). Nov. 2, 2000.
Ozaki, T. et al., “Developmental regulation of transcription of a novel prespore-specific gene (Dp87) inDictyostelium discoideum,” Development. 117(4):1299-308, 1993.
Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.
Xie, M.H. et al., “Interleukin IL-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R,” J. Biol. Chem. 275(40):31335-9, 2000.
Dumoutier, L. et al, “Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), A Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9” Journal of Immunology, Blackwell Scientific Publications, GB, vol. 164-, 2000, pp. 1814-1819.
Dumoutier, L. et al., “Human Interleukin-10-Related T Cell-Derived Inducible Factor: Molecular Cloning and Functional Characterization as an Hepatocyte-Stimulating Factor” Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US, vol. 97, No. 18, Aug. 29, 2000, pp. 10144-10149.
Xie, M-H et al., “Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R” Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD US, vol. 275, No. 40, Oct. 6, 2000, pp. 31335-31339.
Kotenko, Sergei V. et al., “Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes” Journal of Biological Chemistry, American Society of Biological chemists, Baltimore, MD, US, vol. 276, No. 4, Jan. 26, 2001, pp. 2725-2732.
Dumoutier, L. et al., “IL-TIF induces acute phase reactant production by hepatocytes through IL-10Rbeta.” Immunology Letters, vol. 73, No. 2-3 Sep. 2000, p. 261.
Lambert, A. et al., “Novel cytokine IL-22 administrated by adenovirus vector or as recombinant purified protein induces acute-phase responses and renal tubular basophilia in female C57BL/6 mice.” Toxicologic Pathology, vol. 29, No. 6, Nov. 2001, p. 712.
Bork, P., Genome Research 10:398-400, 2000.
Doerks et al., Trends in Genetics 14:248-250, 1998.
Smith et al., Nature Biotechnology 15:1222-1223, 1997.
Brenner, S.E., Trends in Genetics, 15:132-133, 1999.
Mahairas, et al., PNAS, USA, 96(17) 9739-9744 (1999).
Simon L.S., et al. (Jun. 2000), New and future drug therapies for rheumatoid arthritis, Rheumatology 39:36-42.
Liorente L., et al. (2000), Clinical and Biological Effects of Anti-Interleukin-10 Monoclonal Antibody Administration in Systemic Lupus Erythematosus, Arthritis & Rheumatism 43(8):1790-1800.
Van den Bert W. (1998), Joint inflammation and cartilage destruction may occur uncoupled, Springer Semin Immunopathol. 20:149-164.
R&D Systems, Catalog NR, AF582, XP002307633, “Anti-Mouse IL-22 Antibody,” Aug. 22, 2002.
Kotenko, Sergei, “The Family of IL-10-Related Cytokines and receptors: Related, But to What Extent?
Fouser Lynette
Jacobs Kenneth
Pittman Debra D.
Spaulding Vikki
Xuan Dejun
Landsman Robert
Wyeth LLC
LandOfFree
Method of treating psoriasis by administering IL-22... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating psoriasis by administering IL-22..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating psoriasis by administering IL-22... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631249